Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090314 | 0.93 | USP2 (0.51) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL698803 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL18294 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL4693922 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2HPGDRECQLGPR119 | |
| SCHEMBL8525967 | 0.82 | GPR119 (0.59) | HPGDRECQLEPHX1GPR119 | |
| SCHEMBL5053 | 0.80 | HPGD (0.68) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL7858182 | 0.80 | HPGD (0.68) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL861278 | 0.80 | USP2 (0.64) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL18432213 | 0.78 | HPGD (0.71) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL19864899 | 0.78 | HPGD (0.71) | USP2SMN1; SMN2HPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 763 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | claimed |
| EP-3498716-B1 | SULFONYL BEARING THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION AS ANTI-CANCER AGENT | UNIV XIAMEN (CN) | 2024-04-17 | — | — | EP | claimed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| CN-115109011-B | Benzothiazole compound, preparation method and application | 河北师范大学 | 2023-12-15 | — | — | CN | claimed |
| WO-2023081400-A9 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023081400-A1 | DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| CN-115109011-A | Benzothiazole compound, preparation method and application | 河北师范大学 | 2022-09-27 | — | — | CN | claimed |
| CN-108640965-B | 2-substituted-18 beta-glycyrrhetinic acid derivative and application thereof | 沈阳药科大学 | 2021-11-05 | — | — | CN | claimed |
| CN-111954532-A | Anti-tumor multi-drug resistance of heteroaryl amide compounds, application of heteroaryl amide compounds in treating cancer and protein-drug molecular compound | 上海交通大学医学院附属瑞金医院 | 2020-11-17 | — | — | CN | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |
| US-5597841-A | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP, INC. (US) | 1997-01-28 | — | — | US | claimed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | claimed |
| EP-0594257-B1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC (US) | 1996-07-10 | — | — | EP | claimed |
| US-5512589-A | TREATING DEGENERATIVE DISEASES | STERLING WINTHROP INC. (US) | 1996-04-30 | — | — | US | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | claimed |
| EP-0594257-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1994-04-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | USP2 321/4885SMN1; SMN2 2663/4885HPGD 2335/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | USP2 3990/4885SMN1; SMN2 3893/4885HPGD 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.